|
|
Volumn 23, Issue 22, 2005, Pages 4838-4839
|
|
Enrichment designs: Efficiency in development of cancer treatments
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CYTOSTATIC AGENT;
CYTOTOXIC AGENT;
ENCAINIDE;
EPIDERMAL GROWTH FACTOR RECEPTOR;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
ERLOTINIB;
PLACEBO;
TRASTUZUMAB;
ANAMNESIS;
BREAST CANCER;
CANCER ADJUVANT THERAPY;
CANCER SURVIVAL;
CANCER THERAPY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
DRESSLER SYNDROME;
DRUG EFFECT;
DRUG EFFICACY;
DRUG RESPONSE;
DRUG WITHDRAWAL;
EDITORIAL;
GENETIC ANALYSIS;
HAZARD RATIO;
HEART VENTRICLE EXTRASYSTOLE;
HUMAN;
LUNG NON SMALL CELL CANCER;
MORALITY;
OUTCOME ASSESSMENT;
PATIENT SATISFACTION;
PATIENT SELECTION;
PRIORITY JOURNAL;
PROSTATE CANCER;
RANDOMIZED CONTROLLED TRIAL;
TREATMENT RESPONSE;
TUMOR GROWTH;
GENETICS;
METHODOLOGY;
NEOPLASM;
NOTE;
PATHOPHYSIOLOGY;
PROGNOSIS;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS;
HUMANS;
NEOPLASMS;
PATIENT SELECTION;
PROGNOSIS;
RESEARCH DESIGN;
|
|
EID: 24644466557
PISSN: 0732183X
EISSN: None
Source Type: Journal
DOI: 10.1200/JCO.2005.02.913 Document Type: Editorial |
|
Times cited : (34)
|
|
References (7)
|
